GlycoMAb® in the Clinic

A commercial antibody and its GlycoMAb counterpart are currently being compared side-by-side in a clinical study led by GLYCART collaborators. In the production of the clinical grade material, application of GlycoMAb did not change antibody productivity or cell growth. Very stable glycoengineered cell lines were generated and the production process remained unchanged.